JOP20210082A1 - تركيبات تآزرية تشتمل على (r)-2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد و(s)-2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد بنسبة غير راسيمية - Google Patents

تركيبات تآزرية تشتمل على (r)-2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد و(s)-2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد بنسبة غير راسيمية

Info

Publication number
JOP20210082A1
JOP20210082A1 JOP/2021/0082A JOP20210082A JOP20210082A1 JO P20210082 A1 JOP20210082 A1 JO P20210082A1 JO P20210082 A JOP20210082 A JO P20210082A JO P20210082 A1 JOP20210082 A1 JO P20210082A1
Authority
JO
Jordan
Prior art keywords
oxopyrrolidin
butanamide
composition
synergistic compositions
seizure
Prior art date
Application number
JOP/2021/0082A
Other languages
English (en)
Inventor
Michael Scherz
Carlo Farina
Cesare Mannelli Lorenzo Di
Carla Ghelardini
Original Assignee
Metys Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metys Pharmaceuticals AG filed Critical Metys Pharmaceuticals AG
Publication of JOP20210082A1 publication Critical patent/JOP20210082A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة مصاوغات مرآتية من 2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد وذوابات أو بلورات مشتركة مقبولة صيدلانيًا منها بنسبة معينة، وتركيبة صيدلانية تشتمل على التركيبة المذكورة، واستخدامها كدواء واستخدام التركيبات الابتكارية أو التركيبات الصيدلانية في علاج و/أو الوقاية من مرض أو اضطراب يتم اختياره بشكل نمطي ومفضل من الاضطرابات المتعلقة بالنوبات أو الاعتلال العصبي الحسي الطرفي، ويفضل ألم الاعتلال العصبي الطرفي، أو نوبة أو الاكتئاب أو القصور الإدراكي.
JOP/2021/0082A 2018-12-04 2019-12-04 تركيبات تآزرية تشتمل على (r)-2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد و(s)-2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد بنسبة غير راسيمية JOP20210082A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18210106 2018-12-04
PCT/EP2019/083594 WO2020115093A1 (en) 2018-12-04 2019-12-04 Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio

Publications (1)

Publication Number Publication Date
JOP20210082A1 true JOP20210082A1 (ar) 2023-01-30

Family

ID=64604549

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0082A JOP20210082A1 (ar) 2018-12-04 2019-12-04 تركيبات تآزرية تشتمل على (r)-2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد و(s)-2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد بنسبة غير راسيمية

Country Status (20)

Country Link
US (1) US20220047548A1 (ar)
EP (1) EP3890833B1 (ar)
JP (1) JP2022510363A (ar)
KR (1) KR20210099567A (ar)
CN (1) CN113164767A (ar)
AU (1) AU2019391309A1 (ar)
BR (1) BR112021010739A2 (ar)
CA (1) CA3117350A1 (ar)
CO (1) CO2021007055A2 (ar)
EA (1) EA202191485A1 (ar)
EC (1) ECSP21040300A (ar)
ES (1) ES2953785T3 (ar)
HU (1) HUE062575T2 (ar)
IL (1) IL283441A (ar)
JO (1) JOP20210082A1 (ar)
MX (1) MX2021006243A (ar)
PL (1) PL3890833T3 (ar)
SG (1) SG11202105863PA (ar)
WO (1) WO2020115093A1 (ar)
ZA (1) ZA202102701B (ar)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
EP1034826A1 (en) 1999-03-05 2000-09-13 Reuter Chemische Apparatebau Co-crystallization process
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
ITMI20030573A1 (it) 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
CA2488325C (en) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
PL2098526T3 (pl) 2008-02-22 2014-06-30 Neurotune Ag Bicykliczne związki zawierające azot aktywne w stanach przewlekłego bólu
EP2671858A1 (en) * 2012-06-08 2013-12-11 Université Catholique De Louvain Process for chiral resolution of etiracetam
JOP20190251A1 (ar) * 2017-05-31 2019-10-21 Metys Pharmaceuticals AG تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية

Also Published As

Publication number Publication date
ES2953785T3 (es) 2023-11-16
AU2019391309A1 (en) 2021-05-20
HUE062575T2 (hu) 2023-11-28
WO2020115093A1 (en) 2020-06-11
EP3890833B1 (en) 2023-06-07
US20220047548A1 (en) 2022-02-17
EP3890833A1 (en) 2021-10-13
EA202191485A1 (ru) 2021-08-30
JP2022510363A (ja) 2022-01-26
BR112021010739A2 (pt) 2021-08-24
KR20210099567A (ko) 2021-08-12
ZA202102701B (en) 2023-10-25
SG11202105863PA (en) 2021-07-29
CO2021007055A2 (es) 2021-06-10
MX2021006243A (es) 2021-08-11
EP3890833C0 (en) 2023-06-07
ECSP21040300A (es) 2021-07-30
CA3117350A1 (en) 2020-06-11
CN113164767A (zh) 2021-07-23
PL3890833T3 (pl) 2023-09-18
IL283441A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MX2021004431A (es) Procesos novedosos.
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
MX2022001874A (es) Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos.
MY189740A (en) Butylphthalide-telmisartan heterocomplex, preparation method and application thereof
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
PH12018500859A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
PH12019502580A1 (en) Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
EP4039267A4 (en) COMPOSITION, COMPRISING TMEM176B, OR AN EXPRESSION OR ACTIVITY REGULATOR THEREOF, USED AS AN ACTIVE SUBSTANCE, FOR THE PREVENTION OR TREATMENT OF A DEGENERATIVE BRAIN DISEASE
MX2021007142A (es) Compuestos organicos.
ZA202102701B (en) Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio
SG11202106163RA (en) Pharmaceutical composition for prevention or treatment of cancer comprising lactobacillus sakei wikim30 as active ingredient
UA89753C2 (ru) Применение модафинила и антидепрессанта при лечении депрессии и для сокращения времени до начала действия антидепрессанта
MX2023009613A (es) Terapia combinada de obicetrapib y ezetimiba para usarse en pacientes intolerantes a las estatinas que sufren hiperlipidemia o dislipidemia mixta.
PH12021551239A1 (en) Synergistic compositions comprising r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
MX2019013717A (es) Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia.
EA202091523A1 (ru) Терапевтический агент для лечения глаукомы, содержащий агонист fp-рецепторов и -блокатор
MX2021014673A (es) Combinacion de dosis fija de liberacion inmediata de memantina y donepezil.
MX2022001159A (es) Nueva formulacion farmaceutica.
MX2023010542A (es) Uso de mevidaleno y otros moduladores alostéricos positivos d1 para ralentizar la progresión de la enfermedad de parkinson.
ZA202104167B (en) Compounds for use in the treatment of parkinson's disease